Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 50Fibroblast Growth Factor ResearchLiver physiology and pathologyHepatocellular Carcinoma Treatment and Prognosis

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Fibroblast Growth Factor 9 is expressed by activated hepatic stellate cells and promotes progression of hepatocellular carcinoma

Open access

Abstract

Hepatocellular carcinoma (HCC) is closely associated with liver fibrosis. Hepatic stellate cells (HSC) and cancer-associated myofibroblasts are key players in liver fibrogenesis and hepatocarcinogenesis. Overexpression of fibroblast growth factor (FGF) receptors contributes to HCC development and progression. This study aimed to elucidate the role of FGFs in the HSC-HCC crosstalk. Analysis of the expression of the fifteen paracrine FGF-members revealed that FGF9 was only expressed by HSC but not by HCC cells. Also in human HCC tissues, HSC/stromal myofibroblasts were identified as cellular source of FGF9. High expression levels of FGF9 significantly correlated with poor patient survival. Stimulation with recombinant FGF9 induced ERK- and JNK-activation combined with significantly enhanced proliferation, clonogenicity, and migration of HCC cells. Moreover, FGF9 significantly reduced the sensitivity of HCC cells against sorafenib. Protumorigenic effects of FGF9 on HCC cells were almost completely abrogated by the FGFR1/2/3 inhibitor BGJ398, while the selective FGFR4 inhibitor BLU9931 had no significant effect. In conclusion, these data indicate that stroma-derived FGF9 promotes tumorigenicity and sorafenib resistance of HCC cells and FGF9 overexpression correlates with poor prognosis in HCC patients. Herewith, FGF9 appears as potential prognostic marker and novel therapeutic target in HCC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-020-61510-4

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Analysis of paracrine FGFs expression with focus on FGF9 in HCC. (A) Fold mRNA expression levels of paracrine FGFs (subfamilies 1 (FGF1 and FGF2), 4 (FGF4, FGF5 and FGF6), 7 (FGF3, FGF7, FGF10 and FGF22), 8 (FGF8, FGF17, FGF18) and 9 (FGF9, FGF16, FGF20)) in four human HCC cell lines (Hep3B, Huh7, PLC, HepG2) compared to expression in primary human hepatic stellate cells (HSC) from three different donors. (B) “SurvExpress-Biomarker validation for cancer gene expression” database analysis of FGF9 expression (right panel) and corresponding Kaplan-Meier curve for overall survival (left panel) in “TCGA liver cancer” dataset. Computational stratification of patients into “Low Risk” and “High Risk” groups was based on prognostic index and according to the “Maximized Risk Groups” algorithm. (C) Western blot analysis of FGF9 protein levels in primary human hepatic stellate cells (phHSC) and human HCC cell lines (Hep3B, HepG2, Huh7, PLC). (D) Immunofluorescence staining for FGF9 (green) and alpha-smooth muscle actin (alphaSMA; red) of primary human hepatic stellate cells. Nuclei were counterstained using DAPI (blue). (E) Correlation of FGF9 and alpha-sma mRNA expression in human HCC tissues (n = 14). (F) Representative image of immunofluorescence staining for FGF9 (green) and alphaSMA (red) in a human HCC tissue section. Nuclei were counterstained using DAPI (blue).
Figure 1 Analysis of paracrine FGFs expression with focus on FGF9 in HCC. (A) Fold mRNA expression levels of paracrine FGFs (subfamilies 1 (FGF1 and FGF2), 4 (FGF4, FGF5 and FGF6), 7 (FGF3, FGF7, FGF10 and FGF22), 8 (FGF8, FGF17, FGF18) and 9 (FGF9, FGF16, FGF20)) in four human HCC cell lines (Hep3B, Huh7, PLC, HepG2) compared to expression in primary human hepatic stellate cells (HSC) from three different donors. (B) “SurvExpress-Biomarker validation for cancer gene expression” database analysis of FGF9 expression (right panel) and corresponding Kaplan-Meier curve for overall survival (left panel) in “TCGA liver cancer” dataset. Computational stratification of patients into “Low Risk” and “High Risk” groups was based on prognostic index and according to the “Maximized Risk Groups” algorithm. (C) Western blot analysis of FGF9 protein levels in primary human hepatic stellate cells (phHSC) and human HCC cell lines (Hep3B, HepG2, Huh7, PLC). (D) Immunofluorescence staining for FGF9 (green) and alpha-smooth muscle actin (alphaSMA; red) of primary human hepatic stellate cells. Nuclei were counterstained using DAPI (blue). (E) Correlation of FGF9 and alpha-sma mRNA expression in human HCC tissues (n = 14). (F) Representative image of immunofluorescence staining for FGF9 (green) and alphaSMA (red) in a human HCC tissue section. Nuclei were counterstained using DAPI (blue).CC BY · PubMed Central
Figure 2 Effect of FGF9 on tumorigenicity of HCC cells. (A) Proliferation of HCC cell lines Hep3B, HepG2 and PLC stimulated without (ctr.) or with recombinant FGF9 (rFGF9) for 72 h. (B) Quantification of colony number and size (left and middle panel) and representative images (right panels) in anchorage-dependent clonogenic assays with Hep3B cells treated without (ctr.) or with rFGF9. (C) Migratory activity of HCC cells following 4 h treatment with rFGF9 (20 ng/ml; left panel) and representative images of Boyden chamber filters (right panel). Arrowheads indicate migrated cells. (D) Western Blot analysis of phosphorylated ERK and JNK1/2 in rFGF9 (20 ng/ml) treated and control cells. (E) Effects of PD98059 (a selective inhibitor of the MEK/ERK pathway; 10 µM) and SP600125 (JNK inhibitor; 10 µM) on rFGF9 (20 ng/ml)-induced proliferation of Hep3B cells. (F) Effects of PD98059 and SP600125 on proliferation of FGF9 overexpressing (HCCFGF9) and control (HCCctr) Hep3B cells (G) FACS analysis of cell cycle fractions of HCC cells treated with conditioned media (CM) from HSC with siRNA-mediated FGF9 suppression (HSC-siFGF9) or HSC transfected with control siRNA (HSC-siCtr; left panel); representative images (right panel). (H) Volume of spheroids formed by Hep3B cells alone or mixed spheroids of Hep3B cells and control transfected HSC (HSCctr) or Hep3B cells and HSC transfected with an FGF9 expression plasmid (HSCFGF9); representative microscopic images. (Analysis have been performed in triplicates; *p < 0.05).
Figure 2 Effect of FGF9 on tumorigenicity of HCC cells. (A) Proliferation of HCC cell lines Hep3B, HepG2 and PLC stimulated without (ctr.) or with recombinant FGF9 (rFGF9) for 72 h. (B) Quantification of colony number and size (left and middle panel) and representative images (right panels) in anchorage-dependent clonogenic assays with Hep3B cells treated without (ctr.) or with rFGF9. (C) Migratory activity of HCC cells following 4 h treatment with rFGF9 (20 ng/ml; left panel) and representative images of Boyden chamber filters (right panel). Arrowheads indicate migrated cells. (D) Western Blot analysis of phosphorylated ERK and JNK1/2 in rFGF9 (20 ng/ml) treated and control cells. (E) Effects of PD98059 (a selective inhibitor of the MEK/ERK pathway; 10 µM) and SP600125 (JNK inhibitor; 10 µM) on rFGF9 (20 ng/ml)-induced proliferation of Hep3B cells. (F) Effects of PD98059 and SP600125 on proliferation of FGF9 overexpressing (HCCFGF9) and control (HCCctr) Hep3B cells (G) FACS analysis of cell cycle fractions of HCC cells treated with conditioned media (CM) from HSC with siRNA-mediated FGF9 suppression (HSC-siFGF9) or HSC transfected with control siRNA (HSC-siCtr; left panel); representative images (right panel). (H) Volume of spheroids formed by Hep3B cells alone or mixed spheroids of Hep3B cells and control transfected HSC (HSCctr) or Hep3B cells and HSC transfected with an FGF9 expression plasmid (HSCFGF9); representative microscopic images. (Analysis have been performed in triplicates; *p < 0.05).CC BY · PubMed Central
Figure 3 Effects of recombinant FGF9 on HCC cells in combination with sorafenib. (A) Proliferation of HCC cells treated with depicted doses of sorafenib (SF) and rFGF9 (20 ng/ml) for 48 h. (B) Corresponding microscopic images of HCC cells treated w/or w/o rFGF9 (20 ng/ml) and SF (2 µM). (C) Flow cytometric analysis of Annexin V-FITC and propidium iodide (PI) stained HCC cells following treatment with rFGF9 (20 ng/ml) and/or SF (2 µM). The right panel shows representative dot plots. (D) Effects of PD98059 (MEK/ERK inhibitor; 10 µM) or SP600125 (JNK inhibitor; 10 µM) on rFGF9 (20 ng/ml) induced sorafenib resistance of HCC cells. (Analyses have been performed in triplicates; *p < 0.05).
Figure 3 Effects of recombinant FGF9 on HCC cells in combination with sorafenib. (A) Proliferation of HCC cells treated with depicted doses of sorafenib (SF) and rFGF9 (20 ng/ml) for 48 h. (B) Corresponding microscopic images of HCC cells treated w/or w/o rFGF9 (20 ng/ml) and SF (2 µM). (C) Flow cytometric analysis of Annexin V-FITC and propidium iodide (PI) stained HCC cells following treatment with rFGF9 (20 ng/ml) and/or SF (2 µM). The right panel shows representative dot plots. (D) Effects of PD98059 (MEK/ERK inhibitor; 10 µM) or SP600125 (JNK inhibitor; 10 µM) on rFGF9 (20 ng/ml) induced sorafenib resistance of HCC cells. (Analyses have been performed in triplicates; *p < 0.05).CC BY · PubMed Central
Figure 4 Effect of FGFR inhibitors on HCC cells. Effects of BGJ398 (a FGF receptor 1-3 inhibitor, 100 nM) and BLU9931 (a FGF receptor 4 inhibitor, 100 nM) on (A) rFGF9 (20 ng/ml)-induced phosphorylation of ERK and JNK1/2, (B) rFGF9 (20 ng/ml)-induced proliferation, and (C) colony number and (D) colony size anchorage-dependent clonogenic assays with Hep3B cells treated without (ctr.) or with rFGF9 (20 ng/ml). (Analysis have been performed in triplicates; *p < 0.05).
Figure 4 Effect of FGFR inhibitors on HCC cells. Effects of BGJ398 (a FGF receptor 1-3 inhibitor, 100 nM) and BLU9931 (a FGF receptor 4 inhibitor, 100 nM) on (A) rFGF9 (20 ng/ml)-induced phosphorylation of ERK and JNK1/2, (B) rFGF9 (20 ng/ml)-induced proliferation, and (C) colony number and (D) colony size anchorage-dependent clonogenic assays with Hep3B cells treated without (ctr.) or with rFGF9 (20 ng/ml). (Analysis have been performed in triplicates; *p < 0.05).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Cited by

See all 50

Metadata

Authors
Seitz, T., Freese, K., Dietrich, P., Thasler, W. E., Bosserhoff, A., & Hellerbrand, C.
Affiliations
Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
Corresponding author
Hellerbrand, Claus
Venue
Scientific Reports
Published
2020-03-11
Volume
10
Issue
1
Pages
4546-4546
ISSN
2045-2322 (ISSN-L)
OpenAlex
W3010669019
Cited by
47
References
38
Citations by year
2026: 2 · 2025: 6 · 2024: 5 · 2023: 6 · 2022: 11 · 2021: 11 · 2020: 6
FWCI
2.76
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • OPUS FAU (Kooperativer Bibliotheksverbund Berlin-Brandenburg (KOBV), on behalf of the Universitätsbibliothek Erlangen-Nürnberg) (submittedVersion, cc-by)
Funders
Deutsche Forschungsgemeinschaft (HE2458/18, HE2458/15, HE2458/15 and HE2458/18)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
Keywords
FGF9, hepatocellular carcinoma, hepatic stellate cells, liver fibrosis, cancer-associated myofibroblasts, tumor microenvironment, FGFR signaling, sorafenib resistance, BGJ398, FGFR4, ERK activation, JNK activation, tumor cell proliferation and migration, prognostic factors, therapeutic target
MeSH terms
Acrylamides, Cell Movement, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Prognosis, Quinazolines, Tumor Cells, Cultured, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic, Survival Rate, Apoptosis, Cell Proliferation, Receptor, Fibroblast Growth Factor, Type 4, Fibroblast Growth Factor 9, Hepatic Stellate Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fibroblast Growth Factor 9 is expressed by activated hepatic stellate cells and promotes progression of hepatocellular carcinoma. https://app.cochat.ai/papers/10.1038/s41598-020-61510-4
The paper
Seitz, T., Freese, K., Dietrich, P., Thasler, W. E., Bosserhoff, A., & Hellerbrand, C. (2020). Fibroblast Growth Factor 9 is expressed by activated hepatic stellate cells and promotes progression of hepatocellular carcinoma. Scientific Reports. https://doi.org/10.1038/s41598-020-61510-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.